Skip to main content
Premium Trial:

Request an Annual Quote

Celera Deal Signals First Step by Scientific Publisher to Enter Database Realm

NEW YORK, Nov. 20 — Scientific publisher John Wiley & Sons announced on Tuesday an agreement with Celera Genomics that plans to integrate Celera's bioinformatics and genomics data with journal article abstracts and full-text articles.


The partnership represents a significant step into bioinformatics for Wiley's InterScience division, which is developing a new effort to expand beyond journal publishing into database development and curation.


Under this agreement, subscribers will have direct Internet access to crosslinked information from Wiley's journals and Celera's databases. Wiley's scientific, technical, and medical division publishes Proteomics, Genetic Epidemiology, and Comparative and Functional Genomics, as well as many journals of clinical and experimental medicine.


Financial terms of the deal were not disclosed.


"What's driving this is that we have the same content base," said Patrick Kelly, vice president for business development in the scientific, medical, and technical publishing division at Wiley. "The people that are using Celera's information are also using InterScience content. I see it as a natural extension."


Kelly also said that this division of Wiley was planning additional partnerships in bioinformatics and is also looking to develop its own in-house genomics and proteomics database capability. 


"The plot is in the early stages, and we'd be partnering extensively with people who would provide resources," he said in an interview. "But at the end of the day, what we do is identify, recruit, and manage groups of people who evaluate and validate content. We're thinking of ways to leverage these groups."


The 196-year-old company, based in New York, began developing this effort about a year ago, said Kelly, and would likely be launching other similar bioinformatics partnerships within the next year.


"It has raised a few eyebrows" at Wiley, Kelly admitted. "But we're still serving the same customer base, the same user base. I see it as a natural extension of where we are."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more